A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer

Annals of Oncology

Volumn 19, Issue 6, 2008, Pages 1068-1074

  Burstein, H J ^a   Storniolo, A M ^b   Franco, S ^c   Forster, J ^d   Stein, S ^d   Rubin, S ^d   Salazar, V M ^d   Blackwell, K L ^e  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b INDIANA UNIVERSITY   (United States)

^c Memorial Cancer Institute   (United States)

^d GLAXOSMITHKLINE   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Breast cancer; EGFR; ErbB2; Targeted therapy; Trastuzumab; Tyrosine kinase inhibitor

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BILIRUBIN; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; TAXANE DERIVATIVE; TRASTUZUMAB; TYVERB;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER RESISTANCE; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GASTROINTESTINAL DISEASE; GENE AMPLIFICATION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HUMAN TISSUE; HYPERCALCEMIA; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MONOTHERAPY; MORNING DOSAGE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT; SURVIVAL TIME;

EID: 44849108294     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm601     Document Type: Article

References (31)

1. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2: 127-137.
2. Jorissen RN, Walker F, Pouliot N et al. Epidermal growth factor receptor: Mechanisms of activation and signalling. Exp Cell Res 2003; 284: 31-53.
3. Wang Q, Greene MI. The development of targeted therapy in the ErbB system. In Perry MC (ed): American Society of Clinical Oncology Educational Book, 43rd Annual Meeting, Spring 2007. Alexandria, VA: American Society of Clinical Oncology 2007; 79-84.
4. Gullick WJ, Love SB, Wright C et al. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 1991; 63: 434-438.
5. Slamon DJ, Clark GM, Wong SG et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
6. Lin NU, Winer EP. Brain metastases: The HER2 paradigm. Clin Cancer Res 2007: 13: 1648-1655.
7. Herceptin [Package Insert]. San Francisco, CA: Genentech Inc, 2006. Available at: www.gene.com.
8. Tripathy D, Slamon DJ, Cobleigh M et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004; 22: 1063-1070.
9. Montemurro F, Donadio M, Clavarezza M et al. Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist 2006; 11: 318-324.
10. Moulder SL, Yakes FM, Muthuswamy SK et al. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/ neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001; 61: 8887-8895.
11. Rusnak DW, Lackey K, Affleck K et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther 2001; 1: 85-94.
12. Wood ER, Truesdale AT, McDonald OB et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 2004; 64: 6652-6659.
13. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-2743.
14. Geyer CE, Martin A, Newstat B et al. Lapatinib (L) plus capecitabine (C) in HER2+ advanced breast cancer (ABC): Genomic and updated efficacy data. J Clin Oncol 2007; 25 (Suppl): 40s. (Abstr 1035).
15. Gomez HL, Chavez MA, Doval DC et al. Results from a phase II randomized study of lapatinib as first-line treatment for patients with ErbB2-amplified advanced or metastatic breast cancer. Breast Cancer Res Treat 2006; 100: (Suppl): S68. (Abstr 1090).
16. Konecny GE, Pegram MD, Venkatesan N et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006; 66: 1630-1639.
17. Nagata Y, Lan KH, Zhou X et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6: 117-127.
18. Nahta R, Yuan LX, Du Y, Esteva FJ. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: Effects on insulin-like growth factor I signaling. Mol Cancer Ther 2007; 6: 667-674.
19. Nahta R, Yuan LX, Zhang B et al. Insulin-like growth factor-I receptor/ human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005; 65: 11118-11128.
20. Pandolfi PP. Breast cancer - loss of PTEN predicts resistance to treatment. N Engl J Med 2004; 351: 2337-2338.
21. Saez R, Molina MA, Ramsey EE et al. p95HER-2 predicts worse outcome in patients with HER-2 positive breast cancer. Clin Cancer Res 2006; 12: 424-431.
22. Scaltriti M, Rojo F, Ocana A et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 2007; 99: 628-638.
23. Xia W, Husain I, Liu L et al. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. Cancer Res 2007; 67: 1170-1175.
24. Xia W, Liu LH, Ho P, Spector NL. Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016. Oncogene 2004; 23: 646-653.
25. Koehler M, Chan S, Newstat BO et al. Diarrhea events in cancer patients treated with lapatinib. J Clin Oncol 2007; 25 (Suppl): 523s. (Abstr 9125).
26. Sweetman R, Lacouture M, Koehler M et al. Skin events among 1,126 patients treated with lapatinib, an oral dual Erb1/2 tyrosine kinase inhibitor. J Clin Oncol 2007; 25 (Suppl); 518s. (Abstr 9102).
27. Seidman A, Hudis C, Pierri MK et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20: 1215-1221.
28. Suter TM, Cook-Bruns N, Barton C. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast 2004; 13: 173-183.
29. Perez EA, Byrne J, Rappold E et al. Cardiac safety experience in 3558 patients treated with lapatinib. Ann Oncol 2006, 17 (Suppl): Ix224. (Abstr 753P).
30. Gomez HL, Chavez MA, Doval DC et al. Investigation of tumor biomarkers as response predictors in a monotherapy study with lapatinib (L) as a first line treatment in ErbB2 amplified women with breast cancer. J Clin Oncol 2007; 25 ((Suppl)): 580s (Abstr 10562).
31. Giuliani R, Durbecq V, Di Leo A et al. Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC). Eur J Cancer 2007; 43: 725-735.